APLN and cardiac hypertrophy: However, idarubicin and daunorubicin displayed higher activation Z-scores compared to doxorubicin and epirubicin for many canonical pathways including ROS, calcium signaling, necroptosis, cardiac hypertrophy, and cardiac repair (apelin, ErbB, and endothelin-1 signaling).